Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718965 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 826
- Enrollment target
NCT00718965 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 826 participants.
The verdict
NCT00718965, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 826 participants
- Enrollment target
Study Summary
The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of AVE5530 on LDL-C level reduction as adjunct to a controlled diet. The effects of AVE5530 on other lipid parameters will be assessed as secondary objectives.
Interventions
- DRUG Placebo
- DRUG AVE5530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 826 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718965
The ClinicalTrials.gov registry entry for NCT00718965 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 826 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00718965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718965 about?
NCT00718965 is a clinical study titled "Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia". The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of AVE5530 on LDL-C level reduction as adjunct to a con...
What is the current status of trial NCT00718965?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 826 participants. The study started on 2008-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00718965?
The interventions under investigation include: Placebo (DRUG), AVE5530 (DRUG).
Who is sponsoring clinical trial NCT00718965?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.